Skip to main content Accessibility help
  • Print publication year: 2019
  • Online publication date: March 2019

Case 47 - Not Quite So Reserved Anymore

1.Major, EO, Amemiya, K, Tornatore, CS, Houff, SA, Berger, JR. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 1992;5:4973.
2.Saribas, AS, Ozdemir, A, Lam, C, Safak, M. JC virus-induced progressive multifocal leukoencephalopathy. Future Virol 2010;5:313–23.
3.Berger, JR. Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions. J Neurovirol 2003;9(Suppl 1):3841.
4.Mateen, FJ, Muralidharan, R, Carone, M, et al. Progressive multifocal leukoencephalopathy in transplant recipients. Annals Neurol 2011;70:305–22.
5.Yousry, TA, Major, EO, Ryschkewitsch, C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924–33.
6.Sorensen, PS, Bertolotto, A, Edan, G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012;18:143–52.
7.Hunt, D, Giovannoni, G. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring. Pract Neurol 2012;12:2535.
8.Berger, JR, Aksamit, AJ, Clifford, DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013;80:1430–8.
9.Gofton, TE, Al-Khotani, A, O’Farrell, B, Ang, LC, McLachlan, RS. Mefloquine in the treatment of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psych 2011;82:452–5.
10.Brew, BJ, Davies, NW, Cinque, P, Clifford, DB, Nath, A. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nature Rev Neurol 2010;6:667–79.
11.Antinori, A, Cingolani, A, Lorenzini, P, et al. Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol 2003;9(Suppl 1):4753.
12.Steiner, I, Berger, JR. Update on progressive multifocal leukoencephalopathy. Curr Neurol Neurosci Rep 2012;12:680–6.
13.Tan, CS, Koralnik, IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 2010;9:425–37.
14.Padgett, BL, Walker, DL, ZuRhein, GM, Eckroade, RJ, Dessel, BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971;1:1257–60.